Benzi M. Kluger, MD; Janis Miyasaki, MD; Maya Katz, MD; et al.
open access
JAMA Neurol. 2020;77(5):551-560. doi:10.1001/jamaneurol.2019.4992
This randomized clinical trial examines whether outpatient integrated palliative care is associated with patient-centered outcomes and caregiver burden compared with standard care alone among patients with Parkinson disease and related disorders and their caregivers.
Writing Group for the BASILAR Group
free access
JAMA Neurol. 2020;77(5):561-573. doi:10.1001/jamaneurol.2020.0156
This nonrandomized cohort study evaluates the association between endovascular treatment and the clinical outcomes of patients with stroke and acute basilar artery occlusion, compared with patients who received standard medical treatment only.
Bshra Ali A. Alsfouk, PhD; Martin J. Brodie, MD; Matthew Walters, MD; et al.
free access
JAMA Neurol. 2020;77(5):574-581. doi:10.1001/jamaneurol.2020.0032
This cohort study identifies factors associated with poor tolerability of antiseizure medications and examines temporal changes in tolerability.
James F. Howard Jr, MD; Richard J. Nowak, MD; Gil I. Wolfe, MD; et al.
open access
has audio
JAMA Neurol. 2020;77(5):582-592. doi:10.1001/jamaneurol.2019.5125
This randomized clinical trial evaluates the clinical effects of zilucoplan, a subcutaneously self-administered macrocyclic peptide inhibitor of complement component 5, in a broad population of patients with moderate to severe generalized myasthenia gravis.
-
Podcast:
Clinical Effects of Zilucoplan in Patients With Generalized Myasthenia Gravis
William O. Tatum, DO; Lawrence J. Hirsch, MD; Michael A. Gelfand, MD; et al.
free access
JAMA Neurol. 2020;77(5):593-600. doi:10.1001/jamaneurol.2019.4785
This study assesses the value of smartphone videos for diagnosis of epileptic seizures in adult outpatients with epilepsy.
Hooman Kamel, MD; Cenai Zhang, MS; Dawn O. Kleindorfer, MD; et al.
free access
JAMA Neurol. 2020;77(5):601-605. doi:10.1001/jamaneurol.2020.0010
This secondary analysis of the POINT randomized clinical trial examines the association between race and risk of early ischemic stroke recurrence after a minor ischemic stroke or transient ischemic attack among US participants.
Hamidreza Saber, MD, MPH; Jeffrey L. Saver, MD
free access
JAMA Neurol. 2020;77(5):606-612. doi:10.1001/jamaneurol.2019.5061
This cross-sectional study analyzes the distributional, convergent, and predictive validity of National Institutes of Health Stroke Scale (NIHSS) values in the National Inpatient Sample.
Ian Miller, MD; Ingrid E. Scheffer, MBBS, PhD, FRS; Boudewijn Gunning, MD; et al.
open access
JAMA Neurol. 2020;77(5):613-621. doi:10.1001/jamaneurol.2020.0073
This randomized clinical trial evaluates the efficacy and safety of 2 doses of a pharmaceutical formulation of cannabidiol vs placebo for adjunctive treatment of convulsive seizures in patients with Darvet syndrome.
Mads Rasmussen, MD, PhD; Silvia Schönenberger, MD; Pia Löwhagen Hendèn, MD, PhD; et al.
free access
JAMA Neurol. 2020;77(5):622-631. doi:10.1001/jamaneurol.2019.4838
This cohort study investigates whether procedural blood pressure parameters, including specific blood pressure thresholds, are associated with neurological outcomes after endovascular therapy.
Rik Ossenkoppele, PhD; Chul Hyoung Lyoo, MD, PhD; Jonas Jester-Broms, PhD; et al.
open access
JAMA Neurol. 2020;77(5):632-642. doi:10.1001/jamaneurol.2019.5154
This cross-sectional, longitudinal study of amyloid-尾鈥損ositive individuals with mild cognitive impairment or Alzheimer disease dementia examines the factors associated with interindividual differences in brain and cognitive resilience to tau positron emission tomography load and to changes in global cognition over time.